Betmiga
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Prices in online pharmacies:
from 788 rub.
Buy
Betmiga is an antispasmodic drug, a selective beta 3 -adrenoreceptor agonist. Reduces the tone of the smooth muscles of the urinary tract.
Release form and composition
Betmiga is available in the form of extended-release film-coated tablets:
- tablets 25 mg: biconvex, oval, brown, engraved on one side "325" and a graphic representation of the manufacturer; the section shows a white or almost white core (10 pcs. in blisters, in a cardboard box 1 or 3 blisters);
- tablets 50 mg: biconvex, oval, yellow, engraved on one side "355" and a graphic representation of the manufacturer; the cut shows a white or almost white core (10 pcs. in blisters, in a cardboard box 1 or 3 blisters).
Composition for 1 tablet:
- active substance: mirabegron - 25 mg or 50 mg;
- auxiliary components: macrogol 8000, magnesium stearate, macrogol 2,000,000, butylhydroxytoluene, hyprolose;
- film shell: tablets 25 mg - Opadray 03F43159 (macrogol 8000, hypromellose, dye iron oxide red, dye iron oxide yellow); tablets 50 mg - Opadray 03F42192 (macrogol 8000, hypromellose, dye iron oxide yellow).
Indications for use
The drug Betmiga is used for frequent urination, urgency to urinate and overactive bladder (OAB) with symptoms of urinary incontinence.
Contraindications
Absolute:
- hepatic insufficiency of moderate severity when used together with strong inhibitors of the isoenzyme CYP3A;
- severe liver failure;
- severe renal failure when used together with strong inhibitors of the CYP3A isoenzyme;
- renal failure in the terminal stage;
- children and adolescents under 18 years of age (due to the lack of data on the safety and effectiveness of the drug);
- period of pregnancy and lactation;
- hypersensitivity to the main or auxiliary components of the drug.
Relative (the drug Betmiga is used with caution):
- severe renal failure;
- renal failure of mild or moderate severity when used together with strong inhibitors of the CYP3A isoenzyme;
- liver failure of moderate severity;
- hepatic failure of mild severity when used together with strong inhibitors of the isoenzyme CYP3A;
- uncontrolled severe arterial hypertension;
- congenital or acquired lengthening of the QT interval.
Method of administration and dosage
The drug Betmiga is taken orally, regardless of the time of the meal. The tablet should be swallowed whole with water or other liquid.
The recommended dose for adults, including the elderly, patients is 50 mg once a day.
In severe renal and moderate hepatic insufficiency, the daily dose of the drug should not exceed 25 mg; with mild to moderate renal or mild hepatic insufficiency and combined use with strong inhibitors of the CYP3A isoenzyme, the daily dose of Betmiga should also not exceed 25 mg.
Side effects
- gastrointestinal tract: infrequently - gastritis, dyspepsia; rarely - lip swelling;
- cardiovascular system: often - tachycardia; infrequently - atrial fibrillation, heart palpitations;
- organ of vision: rarely - edema of the eyelids;
- musculoskeletal system: infrequently - joint inflammation;
- reproductive system: infrequently - vulvovaginal itching;
- skin and subcutaneous tissue: infrequently - skin rash, itching, macular and papular rash, urticaria; rarely - purpura, leukocytoclastic vasculitis;
- invasions and infections: often - urinary tract infections; infrequently - cystitis, vaginal infection;
- laboratory tests: infrequently - increased activity of liver enzymes, increased blood pressure.
special instructions
The drug Betmiga does not affect the patient's ability to drive vehicles and engage in other potentially hazardous activities.
Drug interactions
The drug Betmiga moderately inhibits the CYP2D6 isoenzyme and weakly inhibits the CYP3A isoenzyme. When Mirabegron is used in high concentrations, the transport of drugs, carried out by P-glycoprotein, is inhibited.
Strengthening the effect of the drug when taken simultaneously with other means is expressed in an increase in the pulse rate.
Terms and conditions of storage
Store at a temperature not exceeding 30 ° C. Keep out of the reach of children.
The shelf life of the drug is 3 years.
Betmiga: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Betmiga 50 mg film-coated tablets of prolonged action 10 pcs. RUB 788 Buy |
|
Betmiga tablets p.p. prolonged action 50mg 10 pcs. 848 RUB Buy |
|
Betmiga 50 mg film-coated tablets of prolonged action 30 pcs. RUB 2405 Buy |
|
Betmiga tablets p.p. prolonged action 50mg 30 pcs. 2477 RUB Buy |
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
